- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.07. | GH Research stock awaits FDA response on clinical hold, says Canaccord | - | Investing.com | ||
| 09.07. | GH Research Responds to FDA Clinical Hold on Depression Treatment GH001 Ahead of Schedule | 1 | Insider Monkey | ||
| 24.06. | JMP bekräftigt Bewertung für GH Research nach positiven Ergebnissen eines Konkurrenten | - | Investing.com Deutsch | ||
| 24.06. | JMP reiterates GH Research stock rating on competitor's positive results | 1 | Investing.com | ||
| 20.06. | GH Research PLC - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 20.06. | GH Research reicht Antwort auf FDA-Klinische Sperre für Depressionsmedikament ein | 1 | Investing.com Deutsch | ||
| 20.06. | GH Research submits response to FDA clinical hold for depression drug | 1 | Investing.com | ||
| GH RESEARCH Aktie jetzt für 0€ handeln | |||||
| 20.06. | GH Research PLC: GH Research Submits Complete IND Hold Response to FDA Ahead of Schedule | 124 | GlobeNewswire (Europe) | DUBLIN, June 20, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing... ► Artikel lesen | |
| 13.06. | GH Research PLC - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 04.06. | Cantor Fitzgerald behält Übergewichtung für GH Research-Aktie bei | 2 | Investing.com Deutsch | ||
| 27.05. | GH Research PLC - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 15.05. | GH Research PLC - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 15.05. | GH Research PLC: GH Research Announces Acceptance of Pharmaceutical Pipeline Presentation and Late-Breaking Posters at the American Society of Clinical Psychopharmacology 2025 Annual Meeting | 68 | GlobeNewswire (Europe) | DUBLIN, May 15, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing... ► Artikel lesen | |
| 08.05. | GH Research PLC - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 08.05. | GH Research PLC: GH Research Reports First Quarter 2025 Financial Results and Provides Business Updates | 184 | GlobeNewswire (Europe) | Primary endpoint met in Phase 2b trial with GH001 in TRD demonstrating -15.5 Point placebo-adjusted MADRS reductionFull response to the IND hold on track for submission in mid-2025Cash, cash equivalents... ► Artikel lesen | |
| 03.03. | Why GH Research PLC (GHRS) is Skyrocketing So Far in 2025 | 6 | Insider Monkey | ||
| 01.03. | GH Research PLC (GHRS): Among the Best Psychedelic Stocks to Buy in 2025 | 2 | Insider Monkey | ||
| 27.02. | GH Research PLC - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 27.02. | GH Research PLC: GH Research Reports Full Year 2024 Financial Results and Provides Business Updates | 224 | GlobeNewswire (Europe) | Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for completion of last patient visit in the open-label extension in Q1 2025Phase 1 clinical trial to evaluate... ► Artikel lesen | |
| 27.02. | GH Research PLC - 20-F, Annual and transition report of foreign private issuers | 1 | SEC Filings |
1 2 3 Weiter >>
42 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 7,412 | +1,73 % | Evotec Aktie vor großem Signal? - Aktuell "verdächtige" Ruhe... | Die Evotec Aktie bewegt sich seit einiger Zeit in einer auffallend engen Handelsspanne zwischen 6,882 und 7,52 Euro. Konstellationen wie diese sind es, die vor starken Kursimpulsen stehen könnte. Mit... ► Artikel lesen | |
| VALNEVA | 2,762 | +0,22 % | Valneva Aktie zündet nach Impfstoff-News - oder doch nur ein Strohfeuer? | Die Valneva Aktie reagierte am Montag mit einem Kurssprung auf die Meldung, dass die Europäische Arzneimittel-Agentur EMA nach positiver Prüfung die Altersbeschränkung für den Chikungunya-Impfstoff... ► Artikel lesen | |
| BIOFRONTERA | 2,440 | -3,56 % | Biofrontera files to sell 13.6M shares of common stock by selling shareholders | ||
| BIOGEN | 110,60 | +0,18 % | Biogen Inc.: Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress | - Data from an analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed improvements in cognition and behavior at Week 68 -
- These findings support... ► Artikel lesen | |
| ILLUMINA | 84,61 | +1,54 % | Illumina Stock: What Went Wrong And Why It's Best To Stay Away | ||
| NANOREPRO | 1,450 | -3,33 % | EQS-DD: NanoRepro AG: Dr. Olaf Stiller, Kauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
26.05.2025 / 14:00... ► Artikel lesen | |
| OCUGEN | 0,870 | -3,16 % | Ocugen, Inc.: Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases | Proposed reverse merger with OrthoCellix, a wholly-owned subsidiary of Ocugen, to create Nasdaq-listed, late clinical-stage regenerative cell therapy company with a first-in-class technology platform... ► Artikel lesen | |
| VAXART | 0,320 | -12,70 % | OTC Markets Group Welcomes Vaxart, Inc. to OTCQX | NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Vaxart, Inc. (OTCQX:... ► Artikel lesen | |
| CYTODYN | 0,244 | -4,69 % | CytoDyn Inc.: CytoDyn Announces Encouraging Survival Data in Patients with Metastatic Colorectal Cancer Previously Treated with Leronlimab | Positive results in patients with advanced mCRC emphasize potential significance of CytoDyn's ongoing Phase II CRC trial Dr. Benjamin Weinberg to present final results at the ESMO Gastrointestinal... ► Artikel lesen | |
| IMMUNIC | 0,800 | +3,76 % | Immunic: Verwaltungsrat genehmigt bis zu 35 Millionen Stock Appreciation Rights für Mitarbeiter | ||
| CEL-SCI | 4,115 | +6,88 % | CEL-SCI Corporation: CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head & Neck Cancer | Strong interest from Saudi investment funds in CEL-SCI, Multikine, and potential joint venture to address the wider Middle East and North Africa market Patient access and reimbursement/sale in... ► Artikel lesen | |
| ADAPTIVE BIOTECHNOLOGIES | 9,500 | +2,11 % | Adaptive Biotechnologies to Report Second Quarter 2025 Financial Results on August 5, 2025 | ||
| BLUEPRINT MEDICINES | 111,15 | 0,00 % | XFRA 2L9: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILBLUEPRINT MED.CORP.DL-001... ► Artikel lesen | |
| MUSTGROW BIOLOGICS | 0,526 | +8,45 % | MustGrow Biologics Corp. Announces Results of Shareholder Meeting | Saskatoon, Saskatchewan--(Newsfile Corp. - June 26, 2025) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow"), is pleased to announce the results of its... ► Artikel lesen | |
| GENPREX | 1,820 | -100,00 % | Genprex, Inc.: Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer at the 2025 AACR Annual Meeting | Both REQORSA Alone and in Combination with LUMAKRAS® Demonstrated Robust Anti-Tumor Effects in Ras Inhibitor Resistant Non-Small Cell Lung Cancer
AUSTIN, Texas... ► Artikel lesen |
GH RESEARCH PLC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 15,000 Euro und damit +11,94 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GH RESEARCH PLC finden Sie auf Wallstreet Online.